CytomX Therapeutics, Inc. (CTMX)
Nasdaq: CTMX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2010
Grade4.4
◀ Past 3.4● Present 5.8▶ Future 3.6
Who owns CytomX Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Fmr LLC holds 14.6% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 5, 2026 says.
Directors and officers
14
report now, of 33 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · 12.4% in Nov 7, 2025
Kynam Capital Management, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.00001 par value per share · 6.9% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock
Bank of America Corporation
SCHEDULE 13G · filed Aug 3, 2026 · Common Stock
Patrick G. Enright
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.00001 par value per share · 7.3% in May 20, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 9.4% in Nov 14, 2025
Perceptive Advisors LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 5.9% in Aug 21, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 5% in Apr 16, 2026
Bvf Partners L P/il
SCHEDULE 13G/A · filed Jul 9, 2025 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 6.8% in Jul 9, 2025
OrbiMed Advisors LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 5.4% in Aug 14, 2025
Seven Fleet Master Fund LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.00001 par value per share ("Common Stock") · reported falling below 5%, from 0.02% in Nov 14, 2025
Seven Fleet Partners LP
SCHEDULE 13G · filed May 20, 2025 · Common Stock, $0.00001 par value per share · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.95% in Jul 29, 2025
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 7% in Aug 14, 2025
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
What CTMX reports owning in othersstakes of 5% or more, and other ties
CytomX Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
7sales
0purchases
3sales on a scheduled plan
4people selling
$2.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 16, 2025 to Oct 16, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 16, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 49 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mccarthy Sean A. | CEO | 3 | $1.7M | 3 | 0 | $0 |
| Belvin Marcia | SVP, Chief Scientific Officer | 1 | $200,000 | 0 | 0 | $0 |
| Ogden Christopher | Chief Financial Officer | 2 | $100,000 | 0 | 0 | $0 |
| Chu Yu-Waye | Chief Medical Officer | 1 | $100,000 | 0 | 0 | $0 |